These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 23860471)

  • 1. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group.
    Woolhouse S; Cooper E; Pickard A
    Int J Drug Policy; 2013 Nov; 24(6):550-7. PubMed ID: 23860471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.
    Treloar C; Rance J; Grebely J; Dore GJ
    Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging stereotypes and changing attitudes: Improving quality of care for people with hepatitis C through Positive Speakers programs.
    Brener L; Wilson H; Rose G; Mackenzie A; de Wit J
    Psychol Health Med; 2013; 18(2):242-9. PubMed ID: 22783938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everybody's got it, but...: situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada.
    Wozniak L; Prakash M; Taylor M; Wild TC
    Int J Drug Policy; 2007 Oct; 18(5):388-96. PubMed ID: 17854727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support.
    Mason K; Dodd Z; Sockalingam S; Altenberg J; Meaney C; Millson P; Powis J
    Int J Drug Policy; 2015 Oct; 26(10):1007-13. PubMed ID: 26005037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
    Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
    Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seeking serenity: living with HIV/AIDS in rural Western Canada.
    Groft JN; Robinson Vollman A
    Rural Remote Health; 2007; 7(2):677. PubMed ID: 17516839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception.
    Safo SA; Batchelder A; Peyser D; Litwin AH
    Harm Reduct J; 2015 Jun; 12():20. PubMed ID: 26092261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
    Treloar C; Newland J; Rance J; Hopwood M
    J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
    Doab A; Treloar C; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users.
    Burt RD; Thiede H; Hagan H
    Drug Alcohol Depend; 2009 Dec; 105(3):215-20. PubMed ID: 19720473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment.
    Batchelder AW; Peyser D; Nahvi S; Arnsten JH; Litwin AH
    Drug Alcohol Depend; 2015 Aug; 153():66-71. PubMed ID: 26096534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients.
    Charlebois A; Lee L; Cooper E; Mason K; Powis J
    J Viral Hepat; 2012 Dec; 19(12):836-42. PubMed ID: 23121361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative study trialling the acceptability of new hepatitis C prevention messages for people who inject drugs: symbiotic messages, pleasure and conditional interpretations.
    Treloar C; Newland J; Maher L
    Harm Reduct J; 2015 Mar; 12():5. PubMed ID: 25884357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
    Litwin AH; Soloway I; Gourevitch MN
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting.
    Treloar C; Rance J;
    Int J Drug Policy; 2014 Sep; 25(5):865-70. PubMed ID: 24559604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV.
    Kresina TF; Bruce RD; Cargill VA; Cheever LW
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S83-8. PubMed ID: 16265621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. At the intersection of marginalised identities: lesbian, gay, bisexual and transgender people's experiences of injecting drug use and hepatitis C seroconversion.
    Deacon RM; Mooney-Somers J; Treloar C; Maher L
    Health Soc Care Community; 2013 Jul; 21(4):402-10. PubMed ID: 23465052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.